Ligand Pharmaceuticals Incorporated (LGND)
Automate Your Wheel Strategy on LGND
With Tiblio's Option Bot, you can configure your own wheel strategy including LGND - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LGND
- Rev/Share 9.4569
- Book/Share 41.4535
- PB 2.5132
- Debt/Equity 0.0056
- CurrentRatio 5.271
- ROIC -0.06
- MktCap 2010069756.0
- FreeCF/Share 1.8502
- PFCF 56.6105
- PE -15.0753
- Debt/Assets 0.0049
- DivYield 0
- ROE -0.1636
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LGND | Stifel | -- | Buy | -- | $143 | April 10, 2025 |
| Initiation | LGND | Oppenheimer | -- | Outperform | -- | $135 | Oct. 3, 2024 |
News
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chief Executive Officer Rich Baxter – Senior Vice President-Investment Operations Tavo Espinoza – Chief Financial Officer Lauren Hay – Vice President-Strategic Planning and Investment Analytics Conference Call Participants Doug Miehm – RBC Capital Markets Matt Hewitt – Craig-Hallum Trevor Allred – Oppenheimer Annabel Samimy – Stifel John Vandermosten – Zacks Operator Thank you for standing by. My name is Kate and I will be your conference operator today.
Read More
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla.
Read More
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D-Fi (FCX-007), Castle Creek's lead candidate, in patients with dystrophic epidermolysis bullosa (DEB).
Read More
About Ligand Pharmaceuticals Incorporated (LGND)
- IPO Date 1992-11-18
- Website https://www.ligand.com
- Industry Biotechnology
- CEO Mr. Todd C. Davis Ph.D.
- Employees 68